LIMINATUS PHARMA, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 |
|---|---|---|
| Operating Activities | ||
| Net Income | $-10.2M | $-3.5M |
| Depreciation & Amortization | — | — |
| Depreciation | $1.8K | — |
| Amortization | — | — |
| Stock-Based Compensation | — | — |
| Net Cash from Operating Activities | $-10.0M | $-1.5M |
| Investing Activities | ||
| Capital Expenditures | $13.1K | — |
| Business Acquisitions | — | — |
| Net Cash from Investing Activities | $-788.1K | $-2.9M |
| Financing Activities | ||
| Dividends Paid | — | — |
| Stock Repurchases | — | — |
| Net Cash from Financing Activities | $11.0M | $3.9M |
| Net Change in Cash | $281.3K | $-378.1K |
| Free Cash Flow | $-10.0M | — |